清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

B7-H3-mediated immune regulation in cancer: biological functions and therapeutic opportunities

作者
Shreya Shreshtha,Lasini Kaluarachchige,Olivia A. Meyer,Genevieve M. Schwarz,Anil S. Basnyat,Jinyu Zhang,Yong Jiang
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:17: 1953747-1953747
标识
DOI:10.3389/fphar.2026.1953747
摘要

B7-H3 (CD276), a member of the B7 family of immunoregulatory ligands, has emerged as an important molecule at the intersection of tumor biology and cancer immunology. Although initially identified as a regulator of T-cell responses, accumulating evidence supports its predominantly immunosuppressive role. B7-H3 is highly expressed across diverse malignancies, including brain, prostate, lung, breast, colorectal, and pediatric cancers, while showing limited expression in most normal adult tissues. Its tumor-associated expression, including tumor vasculature, makes B7-H3 an attractive therapeutic target. Beyond immune regulation, B7-H3 promotes tumor progression through tumor cell-intrinsic mechanisms involving PI3K/AKT, NF-κB, and STAT3 signaling, angiogenesis, epithelial-to-mesenchymal plasticity, and metabolic reprogramming. Within the tumor microenvironment, B7-H3 suppresses T-cell and natural killer cell activity and promotes immunosuppressive macrophage polarization, while its expression can be regulated by metabolic and epigenetic mechanisms. These multifaceted functions have stimulated the development of diverse B7-H3-targeted therapies, including monoclonal antibodies, antibody-drug conjugates, CAR T-cell and Vδ1 T-cell therapies, nanobody-based platforms, and bispecific or trispecific immune cell engagers. Early clinical studies have demonstrated promising antitumor activity, although important challenges regarding efficacy, safety, tumor heterogeneity, and patient selection remain. In this review, we summarize the molecular regulation and biological functions of B7-H3, critically evaluate the current development of B7-H3-targeted therapies, and discuss key challenges and future directions for translating B7-H3-directed strategies into effective cancer treatments.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
8秒前
平淡大船完成签到,获得积分10
13秒前
虚心晓灵完成签到,获得积分10
13秒前
tuimao发布了新的文献求助10
16秒前
Lucas的应助被tuimao采纳,获得10
24秒前
等风的拾荒者完成签到 ,获得积分10
26秒前
31秒前
AiQi完成签到 ,获得积分10
32秒前
伶俐的万言完成签到,获得积分10
46秒前
在水一方的应助被WQY采纳,获得10
46秒前
TingtingGZ发布了新的文献求助10
49秒前
54秒前
WQY发布了新的文献求助10
58秒前
旧城旧巷等旧人完成签到 ,获得积分10
1分钟前
1分钟前
殷勤的鸵鸟完成签到,获得积分10
1分钟前
loen完成签到,获得积分10
1分钟前
杉寒完成签到,获得积分10
1分钟前
务实的绮琴完成签到,获得积分10
1分钟前
1分钟前
ramsey33完成签到 ,获得积分10
1分钟前
tuimao发布了新的文献求助10
2分钟前
Orange的应助被tuimao采纳,获得20
2分钟前
科研通AI6.2的应助被JJYYY采纳,获得10
2分钟前
tfonda完成签到 ,获得积分10
2分钟前
Tree_QD完成签到 ,获得积分10
2分钟前
TingtingGZ发布了新的文献求助10
2分钟前
QQQQQQ完成签到 ,获得积分10
2分钟前
大气翠风完成签到,获得积分10
2分钟前
syvshc的应助被WQY采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
柔弱的妙旋完成签到,获得积分10
3分钟前
和谐的山水完成签到,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
scenery0510发布了新的文献求助10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173213
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780511
捐赠科研通 7767373
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476697